BM Yale

Cold

Spring Harbor Laboratory



HOME | ABOUT | SUBMIT | NEWS & NOTES | ALERTS / RSS

Search

Advanced Search

Q

Comments (I)

SARS-CoV-2 infection in primary schools in northern France: A retrospective cohort study in an area of high transmission

Arnaud Fontanet, D Rebecca Grant, Laura Tondeur, D Yoann Madec, Ludivine Grzelak, Isabelle Cailleau, Marie-Noelle Ungeheuer, Charlotte Renaudat, Sandrine Fernandes Pellerin, Lucie Kuhmel, Isabelle Staropoli, Francois Anna, Pierre Charneau, Caroline Demeret, Timothee Bruel, Olivier Schwartz, D Bruno Hoen **doi:** https://doi.org/10.1101/2020.06.25.20140178

This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should *not* be used to guide clinical practice.

Abstract

Info/History

Metrics

Preview PDF

Abstract

Background: The extent of SARS-CoV-2 transmission among pupils in primary schools and their families is unknown. Methods: Between 28-30 April 2020, a retrospective cohort study was conducted among pupils, their parents and relatives, and staff of primary schools exposed to SARS-CoV-2 in February and March 2020 in a city north of Paris, France. Participants completed a questionnaire that covered sociodemographic information and history of recent symptoms. A blood sample was tested for the presence of anti-SARS-CoV-2 antibodies using a flow-cytometry-based assay. Results: The infection attack rate (IAR) was 45/510 (8.8%), 3/42 (7.1%), 1/28 (3.6%), 76/641 (11.9%) and 14/119 (11.8%) among primary school pupils, teachers, non-teaching staff, parents, and relatives, respectively (P = 0.29). Prior to school closure on February 14, three SARS-CoV-2 infected pupils attended three separate schools with no secondary cases in the following 14 days among pupils, teachers and non-teaching staff of the same schools. Familial clustering of cases was documented by the high proportion of antibodies among parents and relatives of infected pupils (36/59 = 61.0% and 4/9 = 44.4%, respectively). In children, disease manifestations were mild, and

24/58 (41.4%) of infected children were asymptomatic. Interpretation: In young children, SARS-CoV-2 infection was largely mild or asymptomatic and there was no evidence of onwards transmission from children in the school setting.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04325646

Funding Statement

Institut Pasteur, Labex IBEID (ANR-10-LABX-62-IBEID), INCEPTION project (PIA/ANR-16-CONV-0005).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB: Comite de Protection des Personnes Ile de France III

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. 8/8/2020

Palliative Medicine

Pathology

Pediatrics

Pharmacology and Therapeutics

Primary Care Research

Psychiatry and Clinical Psychology

Public and Global Health

Radiology and Imaging

Rehabilitation Medicine and Physical Therapy

Respiratory Medicine

Rheumatology

Sexual and Reproductive Health

Sports Medicine

Surgery

Toxicology

Transplantation

Urology

Supported by Chan Supported by Chan Zuckerberg Initiative